Will The $3bn Stimulus Amid COVID-19 Place Indian Cos Among Goliaths?
INR 51bn Investments Committed Under First PLI Scheme
Executive Summary
Following an INR69bn incentive scheme for APIs, the Indian government has come up with an INR150bn scheme for formulations and more. Will this $3bn push prove to be the one that companies like Sun Pharma and Aurobindo, currently at 36 and 48 respectively in Scrip 100 rankings, need to break into the top league?
You may also be interested in...
Supply Chain Crunch Meets Olympics Shutdown: China, India Drug Makers Brace For Perfect Storm
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile active ingredient supply chain.
Supply Chain Crunch Meets Olympics Shutdown: China, India Drug Makers Embrace For Perfect Storm
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.
Hot Space: PE Advent Snaps Up Second API Manufacturer In India
Private equity investor Advent has acquired API maker ZCL Chemicals in India, its second transaction in a segment seeing rising interest as pharma de-risks sourcing for key ingredients post COVID-19-related turbulence.